

Biocon Biologics South Africa (Pty) Ltd.**BALANCE SHEET AS AT MARCH 31, 2024**

(All amounts in ZAR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>March 31, 2024</u>
ASSETS		
Current assets		
Financial assets		
(i) Trade receivables	1	306
(ii) Cash and cash equivalents	2	<u>18</u>
Total current assets		324
TOTAL		<u><u>324</u></u>
EQUITY AND LIABILITIES		
Equity		
Equity share capital	2	18
Other equity	3	<u>10</u>
Total equity		28
Current liabilities		
Financial liabilities		
(i) Trade payables	4	151
Income-tax liability (net)		4
Provisions	5	36
Other current liabilities	6	<u>105</u>
Total current liabilities		296
TOTAL		<u><u>324</u></u>

Biocon Biologics South Africa (Pty) Ltd.**STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED MARCH 31, 2024**

(All amounts in ZAR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>Period ended</u> <u>March 31, 2024</u>
Income		
Other operating income	7	306
Total revenue (I)		306
Expenses		
Employee benefits expense	8	219
Other expenses	9	73
Total expenses (II)		292
Profit before tax		14
Tax expense		
Current tax		4
Total tax expense		4
Profit for the period		10

Biocon Biologics South Africa (Pty) Ltd.**STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED MARCH 31, 2024**

(All amounts in ZAR Thousands, except share data and unless otherwise stated)

	Period ended March 31, 2024
I Cash flows from operating activities	
Profit after tax	10
<u>Adjustments to reconcile profit before tax to net cash flows:</u>	
Tax expense	4
Operating profit before working capital changes	<u>14</u>
Movements in working capital	
Decrease/(Increase) in trade receivables	(306)
Increase in trade payable, other liabilities and provisions	<u>292</u>
Cash generated used in operations	-
Direct taxes paid	-
Net cash flow (used in) operating activities	<u><u>-</u></u>
II Cash flows from investing activities	
Net cash flow (used in) investing activities	<u><u>-</u></u>
III Cash flows from financing activities	
Proceeds from issue of equity shares	18
Net cash flow generated from financing activities	<u><u>18</u></u>
IV Net increase/(decrease) in cash and cash equivalents (I + II + III)	18
V Effect of exchange differences on cash and cash equivalents held in foreign currency	-
VI Cash and cash equivalents at the beginning of the year	-
VIII Cash and cash equivalents at the end of the year (IV + V + VI)	<u><u>18</u></u>
Reconciliation of cash and cash equivalents as per statement of cash flow	
Cash and cash equivalents	
Balances with banks - on current accounts	18
Cash on hand	-
	<u>18</u>
Total cash and cash equivalents	<u><u>18</u></u>

Biocon Biologics South Africa (Pty) Ltd.**Notes to financial statements for the period ended March 31, 2024**

(All amounts in ZAR Thousands, except share data and unless otherwise stated)

March 31, 2024**1. Trade receivables****Other Receivables**

Outstanding for a period less than six months from the date they are due for payment

Unsecured, considered good

306

306**2. Cash and cash equivalents**

Balances with banks:

On current accounts

18

18**2. Share capital**

Equity share capital

18

18**3. Other equity****Surplus/(deficit) in the statement of profit and loss**

Balance as per the last financial statements

-

Profit / (Loss) for the period

10

Net surplus/(deficit) in the statement of profit and loss10**4. Trade payables**151**5. Provisions****Current**

Compensated absences

36

36**6. Other liabilities****(a) Current liabilities**

Statutory liabilities

105

105

Biocon Biologics South Africa (Pty) Ltd.

Notes to financial statements for the period ended March 31, 2024

(All amounts in ZAR Thousands, except share data and unless otherwise stated)

	Period ended
	March 31, 2024
	<hr/>
7. Other operating income	
Support service cross charge to Group Companies	306
	<hr/>
	306
	<hr/>
8. Employee benefits expense	
Salaries, wages and bonus	219
	<hr/>
	219
	<hr/>
9. Other expenses	
Travelling and conveyance	73
	<hr/>
	73
	<hr/>